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Abstract:
Background: Increasing evidence shows the importance of young age, estrogen receptor (ER), progesterone receptor (PR) status, and 
HER-2 expression in patients with breast cancers.
Patients and methods: We organized an analytic cross-sectional study of 105 women diagnosed with breast cancer who have been 
operated on between 2008 to 2010. We evaluated age, size, hormone receptor status, HER-2 and P53 expression as possible indicator 
of lymph node involvement.
Results: There is a direct correlation between positive progesterone receptor status and being younger than 40 (P , 0.05). Also, 
compared with older women, young women had tumors that were more likely to be large in size and have higher stages (P , 0.05). 
Furthermore patients with negative progesterone receptor status were more likely to have HER-2 overexpression (P , 0.05). The 
differences in propensity to lymph node metastasis between hormone receptor statuses were not statically significant.
Conclusions: Although negative progesterone receptor tumors were more likely to have HER-2 overexpression, it is possible that 
higher stage and larger size breast cancer in younger women is related to positive progesterone receptor status.
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Introduction
The  world’s  most  common  cancer  and  the  second 
main  cause  of  cancer  death  among  women  in  the 
United States is breast cancer.1 The mean age at diag-
nosis is about 63 years in the United States and West-
ern Europe, while it is around 51 years in Iran.
Studies  show  that  the  breast  cancer  in  younger 
women  is  unique  and  needs  a  different  treatment 
strategy than what might be used for older women 
with breast cancer.2–5
Since  breast  cancer  in  older  women  is  more 
common, they have usually been the centre of atten-
tion so the most breast cancer studies have focused on 
older women.6
According to many studies breast cancer in younger 
age  groups  tends  to  be  more  advanced  and  more 
aggressive  than  older  age  groups.2–5,7,8  Also  breast 
tumors in younger age groups were more likely to be 
of higher grade, hormone receptor–negative, poorly 
differentiated, and aneuploid, and to have high S-phase 
fraction, abnormal expression of P53, greater extent 
of  lymphovascular  invasion,  and  overexpression  of 
human epidermal growth factor receptor 2 (HER-2) 
than breast tumors in older age groups.2–5
Local recurrence in women younger than 45 was 
found to be four times more frequent than in women 
older than 65.9 In another retrospective study, local 
recurrence  rate  was  38%  at  10  years,  and  relative 
risk of locoregional recurrence increased by 7% for 
every decreasing year of age in women younger than 
40 who were treated with a primary breast-conserv-
ing  operation  followed  by  adjuvant  radiation  with 
or  without  chemotherapy.10  In  that  study,  the  only 
prognostic  factor  for  locoregional  recurrence  was 
young age. The reason of poor local recurrence in 
women younger than 40 in comparison with women 
older than 40 is still unclear and not fully understood.
Clinically, breast cancer in younger women that 
are diagnosed with a palpable mass have larger tumor 
sizes,  more  lymph  node  metastasis  and  are  more 
invasive cancers than those in older women.2,7,8
Metastasis  to  the  lymph  nodes  is  an  important 
prognostic factor, which indicate advanced disease 
status  with  the  probability  that  cancer  cells  have 
spread to distant sites. At diagnosis, 30% to 50% of 
all breast cancers have spread to the sentinel lymph 
node.11–13
patients and Methods
The study population consisted of 105 patients with 
unilateral breast cancer treated by modified radical 
mastectomy  with  axillary  dissection  from  August 
2008 until March 2010 at the Imam Reza and Shams 
Medical Centers in Tabriz. All types of histologically 
confirmed invasive carcinoma were included.
The  information  was  extracted  retrospectively 
and  included  patient  age,  tumor  size,  stage,  histo-
logic type, estrogen and progesterone receptor status, 
P53, and HER-2 expression. Each of these factors 
was separately evaluated for correlation with lymph 
node involvement and degree of positivity defined as 
number of nodes with metastases.
All analyses were done in a single laboratory using 
the same method, eliminating the problem of inter 
laboratory differences. Patients were divided into two 
age groups: ,40 years and $40 years.
Patient  and  tumor  characteristics  of  age,  tumor 
size in cm (#2 or T1, 2 to 5 or T2, $5 or T3, and T4), 
number of nodes involved (none or N0, one to three 
or N1, four to nine or N2, more than ten or N3, and 
unknown), stage (I, II, III, IV, and unstaged), estrogen 
receptor (ER), progesterone receptor (PR) (positive 
and  negative),  P53  expression,  HER-2  expression 
(positive and negative), and laterality were recorded. 
Tumor size was measured from the largest diameter 
in the gross specimen.
Hormone receptors were considered negative when 
concentration was below 10%. P53 was considered 
positive when nuclear staining was positive in more 
than 10% of tumoral cells. HER-2/neu overexpression 
was considered positive when complete and intense 
membrane staining was observed in more than 10% 
of tumoral cells.
The chi-square test was used for statistical analysis 
for categorical variables. If the expected number in 
any cell of the 2 × 2 contingency table was less than 
five, Fischer’s exact test was used. As the analysis 
involves multiple subgroups, significance was set at 
the 5% level (P , 0.05). The data was analyzed using 
SPSS v.13.0 and EPI Info 6.0.
Our  study  was  in  accordance  with  rules  and 
regulation  of  the  ethics  committee  of  Tabriz 
  University  of  Medical  Sciences,  and  because  the 
study was a retrospective one, the IRB approval was 
not required.hormone receptor in breast cancer
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Results
The distribution of patients by age classifications was 
as follows: 18 patients (17.1%) were younger than 
40 years old, and 87 patients (82.8%) were 40 years 
and older.
Mean  age  at  diagnosis  in  the  younger  women 
was 34 years (range 27 to 39 years) compared with a 
mean age of 53 years in the older women (range 40 
to 80 years).
Stage distribution of the tumors was as follows: 
Stage  I:  13  patients  (12.3%),  stage  II:  40  patients 
(38.1%),  stage  III:  47  patients  (44.7%),  stage  IV: 
3 patients (2.8%) and unstaged: 2 patients (1.9%).
Tumor characteristics in younger women also were 
significantly different from tumor characteristics in 
older women. Younger women had tumors that were 
more  likely  to  have  higher  stage,  larger  size,  and 
  progesterone receptor positive (P , 0.05) as shown in 
Figure 1. Tumor characteristics of the two age groups 
are summarized in Table 1.
77.7% of the younger women had positive lymph 
nodes,  as  compared  to  56.3%  of  the  older  women. 
Although this difference was not significant (P = 0.111), 
it shows an increasing trend in younger patients.
14 (77.7%) of 18 patients younger than 40 years 
old had positive progesterone receptor compared with 
49 (56.3%) of 87 patients 40 years and older. The 
  differences were statistically significant (P , 0.05).
The most common histologic finding was invasive 
ductal  carcinoma,  involving  92  patients  (87.6%). 
55 patients (59.7%) with this histology had lymph 
node  metastasis  compared  to  8  out  of  13  patients 
(61.5%) with mixed cell and other carcinomas. The 
differences were not significant (P = 0.90).
34 out of 57 estrogen receptor positive patients 
(59.6%)  had  lymph  node  involvement;  29  out  of 
48 estrogen receptor negative patients (60.4%) had 
involved nodes, and the difference was not statistically 
significant (P = 0.88).
36 out of 63 progesterone receptor positive patients 
(57.1%)  had  lymph  node  involvement  compared 
with  27  out  of  42  progesterone  receptor  negative 
patients (64.2%). The relation between lymph node 
involvement and progesterone receptor status were 
not statistically significant (P = 0.42). Table 2 shows 
the relation between these pathologic characteristics 
and lymph node status.
We investigated the relation between   progesterone 
receptor  status  and  positive  HER-2/neu.  38  out  of 
42 patients (90.4%) with negative progesterone receptor 
status had positive HER-2/neu, while   progesterone recep-
tor positive patients that had positive HER-2/neu were 
47 out of 63 patients (74.6%). Negative   progesterone 
receptor  status  was  associated  with  HER-2  overex-
pression and this relation was statistically significant 
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Figure 1. Younger women had tumors that were more likely to have higher 
stage (A), larger size (B), and progesterone receptor positive (c).Pourzand et al
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Table 1. Tumor characteristics of the study population.
characteristic Young women  
(n = 18)  
no. of patients (%)
Older women  
(n = 87)  
no. of patients (%)
chi-square 
P-value
Tumor characteristics
Stage ,0.05
 i 1 (5.5) 12 (13.7)
  ii 5 (27.7) 35 (40.2)
  iii 11 (61.1) 36 (41.3)
  iV 1 (5.5) 2 (2.3)
  Unstaged 0 (0.0) 2 (2.3)
Size ,0.05
  T1 1 (5.5) 24 (27.5)
  T2 7 (38.8) 41 (47.1)
  T3 5 (27.7) 17 (19.5)
  T4 5 (27.7) 5 (5.7)
estrogen receptor status 0.68
  Positive 9 (50.0) 48 (55.1)
  negative 9 (50.0) 39 (44.8)
progesterone receptor status ,0.05
  Positive 14 (77.7) 49 (56.3)
  negative 4 (22.2) 38 (43.6)
nodes involved 0.11
  n0 4 (22.2) 36 (41.3)
  n1 6 (33.3) 15 (17.2)
  n2 5 (27.7) 20 (22.9)
  n3 3 (16.6) 14 (16.0)
  Unknown n 0 (0.0) 2 (2.3)
HeR-2 status 0.30
  Positive 13 (72.2) 72 (82.7)
  negative 5 (27.7) 15 (17.2)
p53 status 0.42
  Positive 5 (27.7) 25 (28.7)
  negative 13 (72.2) 62 (71.2)
(P , 0.05). Comparing estrogen receptor status with 
HER-2/neu   expression, just 38 out of 48 patients with 
negative estrogen   receptor (79.1%) had positive HER-2/
neu while 47 out of 57 patients with positive estrogen 
receptor (82.4%) had positive HER-2/neu. No statisti-
cally significant difference was found in the frequency 
of positive HER-2/neu tumors between the negative and 
positive estrogen receptor tumors (Table 3).
A significant correlation was not found between 
the positive lymph nodes, size, or stage with estrogen 
receptor, progesterone receptor status, P53, or HER-2/
neu expression.
Discussion
Breast cancer risk increases with age. In the United 
States  it  is  estimated  that  5%  to  7%  of  breast 
carcinomas  are  presented  in  women  younger  than 
40 years old,14 while in our study it is about 17%. The 
cause of this high percentage compared to the United 
States may be due to a large young population in Iran, 
or there may be genetic and environmental factors.
Clinically, the relation between tumor size and lymph 
node involvement is well known15 and it is the only most 
powerful indicator of poor prognosis in breast cancer.16,17 
Pathologic data consisting of patients with breast cancer 
shows that, at diagnosis, presence of tumor-infiltrated 
lymph nodes is common, with estimates ranging from 
30% to 50% of cases, depending on tumor size.11,13
The younger women had tumors that were clearly 
different from tumors in older women and were charac-
terized by unfavorable biologic parameters. The result 
of our research accounts for the significant within-stage 
disparity between the younger and older women. The 
majority of tumors in younger women had positive hormone receptor in breast cancer
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progesterone receptor and higher stage. There is a rela-
tion between all of these features and more aggressive 
tumors and poorer prognosis. Another analysis also 
found that tumors in young women have lower ER pos-
itivity, higher HER-2/epidermal growth factor receptor 
expression,  and  a  trend  toward  inferior  disease-free 
survival.5 All of these studies support the concept that 
tumors developing in younger women are biologically 
different from tumors in older women and tend to be 
more aggressive with unfavorable biologic markers.
Many  studies  from  Europe  and  America  have 
been  reported  showing  that  young  age  at  diagnosis 
is  as  an  independent  predictor  of  poor  survival.18–22 
The risk factor profile in young women is worse than 
older women. Young women had a tendency to have 
larger tumor sizes, more positive lymph nodes, more 
negative hormone receptors, higher tumor grades than 
older women.2,4,21,23,24 This issue remains controversial, 
as in a retrospective study of breast cancer patients from 
Singapore Chia et al suggested that young women with 
breast cancer had a better survival than older females.25 
It is also in contrast to our study’s finding that younger 
women were more likely to have progesterone recep-
tor positive tumors. Moreover according to our results 
negative progesterone receptor tumors had a tendency 
to have HER-2 overexpression.
As  in  our  study,  Winstanley  et  al26  have  not 
found a significant association between estrogen or 
progesterone receptor and lymph node status.
conclusion
Breast cancer in younger age groups is more aggres-
sive than in older age groups. Although negative pro-
gesterone receptor tumors were more likely to have 
HER-2 overexpression, different biologic behavior of 
breast cancer in younger age groups may be due to 
progesterone receptor positive status.
Additional  studies  should  focus  on  association 
between hormone receptor status, HER-2 expression, 
and lymph nodes metastasis. 
Table 2. Statistical associations between lymph node status with size, histology, and hormone receptor status.
pathologic parameters no. of patients with  
positive lymph nodes (%)
chi-square   
P-value
Tumor size ,0.05
  T1 11 (44.0)
  T2 28 (58.3)
  T3 15 (68.1)
  T4 9 (90.0)
Histology 0.90
  invasive ductal carcinoma 55 (59.7)
  invasive mixed cell + others 8 (61.5)
estrogen receptor status 0.88
  Positive 34 (59.6)
  negative 29 (60.4)
progesterone receptor status 0.42
  Positive 36 (57.1)
  negative 27 (64.2)
Table 3. Relation of heR-2/neu expression with hormone receptor status.
Hormone receptor no. of patients  
with negative HeR-2/neu (%)
no. of patients  
with positive HeR-2/neu (%)
chi-square 
P-value
estrogen receptor status 0.14
  Positive 10 (17.5) 47 (82.4)
  negative 10 (20.8) 38 (79.1)
progesterone receptor status ,0.05
  Positive 16 (25.4) 47 (74.6)
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